K. ARAVIND
Cipla is a leading pharmaceutical company. This biotechnology company, which manufactures medicines and pharmaceutical ingredients, has a presence in India, the United States, South Africa and other countries.
Due to COVID-19, there is a huge demand for generic drugs globally. Cipla is ready to take advantage of this demand. Cipla is currently active in the production of drugs used to treat corona virus infections. The company also produces significant amounts of drugs for viruses such as HIV.
In general, pharma stocks are likely to perform differently from the general market. The rise in demand for medicines and the depreciation of the rupee are positive factors for pharma companies.
In the current market, investors are increasingly looking to invest in the defensive sectors such as FMCG and pharma. This method is the factor that leads to the rise in the price of stocks like Cipla.
India is a major power in the production of generic drugs. No country in the world can ignore Indian pharma companies as demand for generic drugs rises. Therefore, pharma stocks are likely to continue to perform well in the coming years.
